This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter

2 hours ago 2

Jonathan Ponciano, The Motley Fool

Sun, May 24, 2026 astatine 9:33 AM CDT 4 min read

On May 15, 2026, Deep Track Capital disclosed a caller presumption successful Alumis (NASDAQ:ALMS), acquiring 6,772,595 shares—an estimated $169.31 cardinal commercialized based connected quarterly mean pricing.

What happened

According to a May 15, 2026 SEC filing, Deep Track Capital reported acquiring 6,772,595 shares of Alumis (NASDAQ:ALMS) during the archetypal 4th of 2026. The estimated transaction worth was $169.31 million, based connected the period’s mean unadjusted closing price. As of March 31, 2026, the fund’s Alumis involvement was valued astatine $149.20 million, reflecting some the acquisition and banal terms changes during the quarter.

What other to cognize

Top 5 holdings aft the filing:
- NASDAQ:GH: $308.35 cardinal (6.4% of AUM)
- NASDAQ:IMVT: $286.33 cardinal (5.9% of AUM)
- NASDAQ:TARS: $252.54 cardinal (5.2% of AUM)
- NASDAQ:PCVX: $249.87 cardinal (5.2% of AUM)
- NASDAQ:GPCR: $206.29 cardinal (4.3% of AUM)
As of Friday, shares of Alumis were priced astatine $22.02, up astir 355% implicit the past twelvemonth and good outperforming the S&P 500, which is up astir 28% successful the aforesaid period.

Company overview

Metric

Value

Price (as of Friday)	$22.02
Market capitalization	$2.8 billion
Revenue (TTM)	$8.40 million
Net income (TTM)	($237.41 million)

Company snapshot

Alumis develops clinical-stage biopharmaceutical products targeting autoimmune and neuroinflammatory diseases, with pb assets including ESK-001 and A-005.
The steadfast operates a research-driven concern exemplary focused connected advancing proprietary TYK2 inhibitors done objective trials toward imaginable commercialization.
It targets healthcare providers and patients affected by autoimmune disorders specified arsenic plaque psoriasis, systemic lupus erythematosus, and neurodegenerative diseases.

Alumis is simply a biotechnology institution specializing successful the improvement of caller therapies for autoimmune and neuroinflammatory conditions. It leverages expertise successful allosteric TYK2 inhibition to beforehand a pipeline of differentiated objective candidates. With a absorption connected unmet aesculapian needs, Alumis aims to found a competitory borderline done innovative subject and targeted objective improvement strategies.

What this transaction means for investors

Deep Track has a past of making concentrated healthcare investments, and Alumis fits that playbook arsenic a late-stage biotech with aggregate shots connected extremity and respective perchance value-defining catalysts implicit the adjacent year.

The communicative is progressively centered connected envudeucitinib, the company's TYK2 inhibitor for autoimmune diseases. Recent Phase 3 psoriasis information showed PASI 90 effect rates of 68.0% and 62.1% by Week 24, with PASI 100 rates reaching 41.0% and 39.5%. Management says it remains connected way to taxable an NDA successful the 4th fourth of this year, portion perchance pivotal Phase 2b lupus information are expected successful the 3rd quarter.

CEO Martin Babler said the results reenforce the drug's imaginable to "reshape the psoriasis attraction landscape" and described envudeucitinib arsenic a imaginable "pipeline successful a pill" with opportunities crossed further immune-mediated diseases.

Financially, Alumis ended the 4th with $569.5 cardinal successful cash, currency equivalents, and marketable securities and expects that superior to money operations into the 4th fourth of 2027.

For semipermanent investors, the thesis is straightforward. If upcoming lupus information and the planned psoriasis filing spell well, today's valuation could look conservative. If either disappoints, the stock's singular tally whitethorn beryllium hard to sustain.

Read Entire Article